MOTS-C dosage chart
10 mg Vial
MOTS-c is dosed at 200 mcg–1 mg administered daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. Most protocols titrate gradually over roughly 10 weeks. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range
- 200–1,000 mcg once daily (gradual titration over 10 weeks).
- Easy measuring
- At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.
Dosing schedule
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 12 units (0.12 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 18 units (0.18 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 24 units (0.24 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 30 units (0.30 mL) |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake vigorously).
- 4Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 5Use within 7 days for optimal potency.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose, injection site, and any observations to maintain consistency.
- Discontinue use and consult a medical professional if any concerning symptoms arise.
How This Works
MOTS-c functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise. Its primary mechanism is AMPK activation through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into an energy-efficient mode – enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis.
MOTS-c can also translocate to the cell nucleus under stress conditions and upregulate antioxidant and stress-response genes. This retrograde signaling from mitochondria to nucleus increases expression of cytoprotective enzymes, helping cells cope with oxidative stress. Research indicates MOTS-c may also modulate mTOR and inflammatory pathways, contributing to lifespan and healthspan effects. Its actions resemble those of exercise and metformin at a cellular level, making it of great interest for metabolic disorders, obesity, and aging research.
Potential Benefits & Side Effects
Observations from preclinical literature (no human clinical trials completed to date):
Note: These benefits have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires clinical studies.
- Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; prevents diet-induced insulin resistance.
- Weight & Fat Reduction: Prevents obesity and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation.
- Post-Menopausal Metabolism: Mitigates metabolic decline in ovariectomized mice; prevents menopause-related fat gain and insulin resistance.
- Physical Performance: Enhances exercise capacity and counters age-related frailty; old mice ran 2× longer on treadmill tests.
- Organ Protection: Reduces liver fat accumulation, improves cardiac function, and may support cognitive function in preliminary studies.
- Bone & Immunity: Promotes osteoblast activity, inhibits osteoclast formation; modulates immune aging and protects pancreatic islet cells in autoimmune diabetes models.
- Safety: No adverse effects reported in preclinical studies; human tolerability unknown. A modified analog (CB4211) showed good tolerability in a Phase 1 trial.
Lifestyle Factors
Complementary strategies for best outcomes based on MOTS-c’s metabolic mechanisms.
- Pair with a balanced, protein-forward diet tailored to energy needs.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations and AMPK signaling.
- Prioritize sleep (7–9 hours) and stress management to support mitochondrial health and recovery.
- Consider intermittent fasting or caloric restriction, which may synergize with MOTS-c’s AMPK-mediated effects.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources:
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 90° (45° if very lean) into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily over a few seconds.
- Withdraw needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
- Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and lipohypertrophy.
- Dispose of used syringes immediately in a proper sharps container (never reuse needles).
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-c is an experimental compound for research use only. No clinical trials have been completed in humans. Always consult qualified healthcare providers before starting any new therapy.
MOTS-C dosage FAQs
How much bacteriostatic water do you use to reconstitute MOTS-C?
Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration. for a 10 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the MOTS-C dosing schedule look like?
Weeks 1–2 — 200 mcg (0.2 mg) — 6 units (0.06 mL); Weeks 3–4 — 400 mcg (0.4 mg) — 12 units (0.12 mL); Weeks 5–6 — 600 mcg (0.6 mg) — 18 units (0.18 mL); Weeks 7–8 — 800 mcg (0.8 mg) — 24 units (0.24 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for MOTS-C?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake vigorously).
How should reconstituted MOTS-C be stored?
Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency..
How many insulin syringe units equal a MOTS-C dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is MOTS-C approved for human use?
No. MOTS-C is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.